To assess the prognostic value of IRGPI in patients receiving immunotherapy, we validated it by performing the prognostic analysis using the cohort of Imvigor‐210 (urothelial carcinoma, UC) treated with anti‐PD‐L1 therapy and GSE78220 (melanoma) treated with anti‐PD‐1 therapy. The gene discussed is CD274; the disease is urothelial carcinoma.